By Ben Glickman Shares of Synlogic fell sharply after the company opted to cease operations after stopping a clinical trial. The stock was down 55% to $1.56.
Health-care companies rose amid promising drug developments. Foghorn Therapeutics shares jumped by 56% after the biotech company said Eli Lilly will conduct.
New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments.
By Colin Kellaher INmune Bio on Tuesday said the U.S. Food and Drug Administration has lifted the full clinical hold on the immunology company's Alzheimer's.